ESTRO 2024 - Abstract Book

S1630

Clinical - Lung

ESTRO 2024

with cCRT were younger and fitter (as shown in Table 1), and further studies are required to see if the effect is independent of these factors.

Keywords: NSCLC, Curative-intent, Chemoradiotherapy

References:

[1] The Royal College of Physicians. National Lung Cancer Audit annual report 2017 (for the audit period 2016), 2018.

880

Poster Discussion

RAPID-RT: An inclusive study using real-world data to evaluate patient outcomes after radiotherapy

Rebecca J Holley 1,2 , Hannah Turner-Uaandja 3 , Brian Turner 4 , Leila Hamrang 4 , Sarah Devaney 5 , Soren Holm 6 , Arbaz Kapadi 7 , Catherine Bowden 5 , Kate Wicks 1 , Annie Keane 3 , Tjeerd can Staa 8 , Gareth Price 1,2 , Corinne Faivre-Finn 1,2 1 The University of Manchester, Cancer Sciences, Manchester, United Kingdom. 2 The Christie NHS Foundation Trust, Radiotherapy related research, Manchester, United Kingdom. 3 Vocal, Patient involvment, Manchester, United Kingdom. 4 Patient, Patient, Manchester, United Kingdom. 5 The University of Manchester, Law, Manchester, United Kingdom. 6 The University of Manchester, Ethics, Manchester, United Kingdom. 7 The University of Manchester, Psychology & Mental Health, Manchester, United Kingdom. 8 The University of Manchester, Informatics, Imaging & Data Sciences, Manchester, United Kingdom Randomised control trial (RCTs) are the gold standard to provide evidence for changes in radiotherapy practice. However, barriers to enrolment often limit participation in trials, with many patient groups (e.g. elderly, multimorbid, socioeconomically-deprived, ethnic minorities) often under-represented, raising concerns about the generalisability of RCT evidence. Furthermore, conventional clinical trials can be challenging to conduct in rapidly evolving technical environments like the successive updating of radiotherapy techniques and technologies. As a result changes in radiotherapy practice are often introduced with little or insufficient evidence of their impact on patient outcomes. Pragmatic trials often use real world data (RWD), the information collected about all patients during their normal treatment pathways, to increase study participation and their external validity. These trial designs offer the ability to conduct inclusive research and generate rapid results for maximal patient benefit. Purpose/Objective:

Recent evidence 1,2 has shown that radiation dose to the base of the heart is associated with poor survival in patients after thoracic radiotherapy. On the strength of this evidence, The Christie NHS Foundation Trust implemented in